Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com - Truist Securities has reiterated its Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) while maintaining its $25.00 price target. According to InvestingPro data, analysts’ targets range from $18 to $29, with the stock currently trading at $18.87. The company’s overall financial health score is rated as "GOOD."
The firm’s decision follows a recap call discussing Olanzapine LAI (long-acting injectable) data that was presented at the recent Psychiatric Congress over the weekend.
Truist Securities noted potential upside to management’s guidance for the company’s schizophrenia treatment franchise, which includes the Olanzapine LAI product.
The firm specifically mentioned "additional nuggets" of information gleaned from the recap call about the data presentation that reinforced its positive outlook on the stock.
Teva Pharmaceutical’s development of long-acting injectable treatments represents part of its strategy in the psychiatric medication market, particularly for schizophrenia patients. As a prominent player in the pharmaceuticals industry, the company maintains a solid gross profit margin of 49.6%.
In other recent news, Teva Pharmaceutical Industries reported its second-quarter earnings for 2025, with an earnings per share of $0.66, surpassing the forecast of $0.63. However, the company’s revenue of $4.2 billion fell short of the expected $4.28 billion. In addition to the earnings report, Teva announced the FDA approval and U.S. launch of its generic version of Saxenda, a GLP-1 drug specifically indicated for weight loss, marking a significant development in the weight loss therapy market. Furthermore, Teva shared positive results from its Phase 3 SOLARIS trial for its long-acting injectable olanzapine treatment for schizophrenia, reporting no cases of Post-Injection Delirium/Sedation Syndrome after approximately 4,000 injections. This safety profile could potentially enhance the drug’s commercial viability. Goldman Sachs maintained its Buy rating on Teva with a $25.00 price target, following the positive trial data. The analyst firm noted that the safety results are crucial for commercial success. These developments highlight Teva’s ongoing efforts in expanding its pharmaceutical portfolio and addressing market demands.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.